Gregg Smith

Gregg Smith Email and Phone Number

Experienced Drug Product and Corporate Development Executive @ Anaxis Pharma
australia
Gregg Smith's Location
Middle Park, Victoria, Australia, Australia
Gregg Smith's Contact Details

Gregg Smith personal email

About Gregg Smith

Accomplished senior executive with over 20 years' international experience in the biotech/pharma industry. Instrumental in the development of the recently approved myelofibrosis therapy, momelotinib (OJJARA/OMJJARA), and in its $1.9B sale to GSK. Extensive drug development experience, including leadership of 10+ preclinical and clinical programs, spanning from the discovery/development interface to Phase 1/2 clinical trials. Executive participation in multiple FDA regulatory interactions; Phase 3 study design and execution, and NDA preparation. Substantive expertise in corporate development and strategy. Lead/senior deal team member for M&A and licensing transactions totalling ~ US$3.5B.Therapeutic areas include haematology/oncology, inflammation, anti-infectives, neurology and pain.

Gregg Smith's Current Company Details
Anaxis Pharma

Anaxis Pharma

View
Experienced Drug Product and Corporate Development Executive
australia
Website:
anaxispharma.com
Employees:
2
Gregg Smith Work Experience Details
  • Gregg Smith Consulting
    Director
    Gregg Smith Consulting Sep 2013 - Present
    I provide strategic clinical and nonclinical drug development consultancy services to the biotechnology industry, as well as corporate development for licensing and due diligence activities.
  • Anaxis Pharma
    Drug Development Adviser
    Anaxis Pharma Oct 2024 - Present
    Melbourne, Victoria, Australia
    Anaxis Pharma is developing novel inhibitors / modulators of cell death, specifically necroptosis, an inflammatory form of programmed cell death. This process is central to and dysregulated in chronic inflammatory disease. Targeting necroptosis fulfils an unmet medical need for patients with diseases including irritable bowel disease, Crohn’s disease, liver fibrosis and reperfusion injury.
    View
  • Synthesis Research
    Drug Development Adviser
    Synthesis Research Jan 2024 - Present
    Melbourne, Victoria, Australia
    SYNthesis Research manages a portfolio of investee early-stage biopharmaceutical companies developing platform technologies and delivering first in class/best in class small molecule drugs for indications including oncology and chronic inflammatory diseases.
    View
  • Sierra Oncology
    Senior Vice President, Corporate Development & Strategy
    Sierra Oncology May 2021 - Feb 2023
    Sierra Oncology was a NASDAQ-listed biopharmaceutical company based in San Mateo, California. The company developed momelotinib, a JAK1, JAK2 and ACVR1 inhibitor for myelofibrosis. The company's pipeline also included SRA737, a Checkpoint kinase 1 (Chk1) inhibitor and SRA141, a CDC7 inhibitor.Sierra Oncology was acquired by GSK in July 2022 for $1.9B.
    View
  • Sierra Oncology
    Senior Vice President, Drug Development
    Sierra Oncology Nov 2015 - May 2021
    View
  • Sierra Oncology Australia Pty Ltd
    Executive Director
    Sierra Oncology Australia Pty Ltd Nov 2015 - Jul 2022
  • Gilead Sciences
    R&D Executive
    Gilead Sciences Feb 2013 - Aug 2013
    View
  • Ym Biosciences
    Vice President: Drug Development & Vice-President: Australian Operations
    Ym Biosciences 2010 - 2013
    YM BioSciences was a Canadian public life-sciences company developing the Australian-invented JAK-kinase inhibitor, momelotinib. YM was acquired by Gilead in February 2013 for $510 million.
  • Cytopia Ltd
    Vice President: Drug Development & Operations
    Cytopia Ltd 2005 - 2010
    Cytopia was an Australian public biotechnology company, developing a pipeline of drug candidates for a range of cancers, immune diseases and cardiovascular disorders. The company merged with YMBioSciences in January 2010.
  • Cerylid Biosciences
    Vice President: Drug Development
    Cerylid Biosciences 2004 - 2005
  • Kinacia Pty Ltd
    Head Of Drug Development
    Kinacia Pty Ltd 2001 - 2004

Gregg Smith Education Details

Frequently Asked Questions about Gregg Smith

What company does Gregg Smith work for?

Gregg Smith works for Anaxis Pharma

What is Gregg Smith's role at the current company?

Gregg Smith's current role is Experienced Drug Product and Corporate Development Executive.

What is Gregg Smith's email address?

Gregg Smith's email address is gd****@****ail.com

What schools did Gregg Smith attend?

Gregg Smith attended The University Of Queensland, La Trobe University, The University Of Queensland.

Who are Gregg Smith's colleagues?

Gregg Smith's colleagues are Anne Hempel, Martine Keenan.

Not the Gregg Smith you were looking for?

View similar profiles

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.